This Alzheimer’s drug slowed cognitive decline in some patients. Analysts say it could become a blockbuster hit.
Full results of Biogen and Eisai's Alzheimer's study on lecanemab give some credence to a controversial hypothesis.
Full Article
This Alzheimer’s drug slowed cognitive decline in some patients. Analysts say it could become a blockbuster hit.
Business Insider
0 shares
1 views
You might like
Related news coverage
This Alzheimer’s drug slowed cognitive decline in some patients. Analysts say it could become a blockbuster hit
Glassdoor Biogen and Eisai just released the full phase 3 data of a new Alzheimer's drug, lecanemab. The medication slowed the rate..
Upworthy